Nutritional supplements for patients being treated for active visceral leishmaniasis. by Custodio, Estefanía et al.
Cochrane Database of Systematic Reviews
Nutritional supplements for patients being treated for active
visceral leishmaniasis (Review)
Custodio E, López-Alcalde J, Herrero M, Bouza C, Jimenez C, Storcksdieck genannt Bonsmann S,
Mouratidou T, López-Cuadrado T, Benito A, Alvar J
Custodio E, López-Alcalde J, Herrero M, Bouza C, Jimenez C, Storcksdieck genannt Bonsmann S, Mouratidou T, López-Cuadrado T, Benito A,
Alvar J.
Nutritional supplements for patients being treated for active visceral leishmaniasis.
Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD012261.
DOI: 10.1002/14651858.CD012261.pub2.
www.cochranelibrary.com
Nutritional supplements for patients being treated for active visceral leishmaniasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
12DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iNutritional supplements for patients being treated for active visceral leishmaniasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Nutritional supplements for patients being treated for active
visceral leishmaniasis
Estefanía Custodio1 ,2a , Jesús López-Alcalde3,4b , Mercè Herrero5, Carmen Bouza6 , Carolina Jimenez7, Stefan Storcksdieck genannt
Bonsmann1 , Theodora Mouratidou8 , Teresa López-Cuadrado9 , Agustin Benito2, Jorge Alvar7
1European Commission, Joint Research Centre (JRC), Ispra, Italy. 2National Centre of Tropical Medicine, Instituto de Salud Carlos III
(ISCIII), Madrid, Spain. 3Faculty of Medicine, Universidad Francisco de Vitoria (UFV) Madrid, Madrid, Spain. 4Clinical Biostatistics
Unit, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. 5Department of Neglected Tropical Diseases,
World Health Organization (WHO), Geneva, Switzerland. 6Healthcare Technology Assessment Agency, Instituto de Salud Carlos
III (ISCIII), Madrid, Spain. 7Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland. 8Department of Physiatry and
Nursing, University of Zaragoza, Zaragoza, Spain. 9National Centre for Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid,
Spain
aBoth authors contributed equally to this work. bBoth authors contributed equally to this work
Contact address: Estefanía Custodio, European Commission, Joint Research Centre (JRC), Ispra, Italy. ecustodio2014@gmail.com.
Editorial group: Cochrane Infectious Diseases Group.
Publication status and date: New, published in Issue 3, 2018.
Citation: Custodio E, López-Alcalde J, Herrero M, Bouza C, Jimenez C, Storcksdieck genannt Bonsmann S, Mouratidou T, López-
Cuadrado T, Benito A, Alvar J. Nutritional supplements for patients being treated for active visceral leishmaniasis. Cochrane Database
of Systematic Reviews 2018, Issue 3. Art. No.: CD012261. DOI: 10.1002/14651858.CD012261.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Visceral leishmaniasis (VL) is a disease caused by a parasite, which can lead to death if untreated. Poor nutritional status hastens the
progression of VL infection, and VL worsens malnutrition status. Malnutrition is one of the poor prognostic factors identified for
leishmaniasis. However, the effects of nutritional supplementation in people treated for VL are not known.
Objectives
To assess the effects of oral nutritional supplements in people being treated with anti-leishmanial drug therapy for VL.
Search methods
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, and
two trial registers up to 12 September 2017. We checked conference proceedings and WHO consultative meeting reports, the reference
lists of key documents and existing reviews, and contacted experts and nutritional supplement companies.
Selection criteria
Randomized controlled trials (RCTs), quasi-randomized controlled trials (quasi-RCTs), and non-randomized controlled trials (NRCTs)
of any oral nutritional supplement, compared to no nutritional intervention, placebo, or dietary advice alone, in people being treated
for VL.
Data collection and analysis
Two review authors independently screened the literature search results for studies that met the inclusion criteria. We had planned for
two review authors to independently extract data and assess the risk of bias of the included studies. We planned to follow the Cochrane
standard methodological procedures for assessing risk of bias and analysing the data.
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Main results
We identified no eligible studies for this review, either completed or ongoing.
Authors’ conclusions
We found no studies, either completed or ongoing, that assessed the effects of oral nutritional supplements in people with VL who
were being treated with anti-leishmanial drug therapy. Thus, we could not draw any conclusions on the impact of these interventions
on primary cure of VL, definitive cure of VL, treatment completion, self-reported recovery from illness or resolution of symptoms,
weight gain, increased skinfold thickness, other measures of lean or total mass, or growth in children.
This absence of evidence should not be interpreted as evidence of no effect for nutritional supplements in people under VL treatment.
It means that we did not identify research that fulfilled our review inclusion criteria.
The effects of oral nutritional supplements in people with VL who are being treated with anti-leishmanial drug therapy have yet to be
determined by rigorous experimental studies, such as cluster-randomized trials, that focus on outcomes relevant for patients.
P L A I N L A N G U A G E S U M M A R Y
Nutritional supplements for patients who are being treated for active visceral leishmaniasis
What is the aim of this review
The aim of this Cochrane review was to find out whether oral nutritional supplements could help people who were being treated for
visceral leishmaniasis (VL). We tried to collect and analyse all relevant studies that answered this question.
Key messages
We found no trials, either completed or ongoing, that answered our review question. Thus, good quality evidence on the effects of oral
nutritional supplements in people who are being treated with anti-leishmanial drug therapy is needed. This evidence could be obtained
if a large, well done, randomized clinical trial was undertaken.
What was studied in this review
VL, also known as kala-azar, is an infection that has a worldwide distribution. It can lead to death if untreated. Malnutrition and VL
are interconnected health problems. On the one hand, malnutrition may hasten the progression of the infection, while on the other
hand, VL worsens the malnutrition status of the individual. Also, if a person with VL is malnourished, she or he does not respond as
well to the treatment for leishmaniasis. As VL frequently affects people living in poor countries, with limited access to optimal diets,
giving additional nutrients to people receiving treatment for VL may improve their nutrition, and thus, their health.
We searched for trials that evaluated the effects of providing any oral nutritional supplement, compared with placebo, dietary advice,
or no nutritional intervention, in people who were being treated for VL.
What are the main results of this review?
We found no trials, either completed or ongoing, that answered our review question. Thus, there is no high quality evidence from trials
to inform healthcare professionals about the effects of oral nutritional supplements in people who are being treated for VL.
This absence of evidence should not be interpreted as evidence of no effect for nutritional supplements in people under VL treatment.
It means that we did not identify any eligible research for this review, and that the effects of oral nutritional supplements have yet to
be determined by rigorous studies.
How up-to-date is this review
We searched for studies that had been published up to 12 September 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nutritional supplements versus no nutritional supplements for people who are being treated for active VL
Patient or population: people who are being treated for act ive VL
Setting: any
Intervention: nutrit ional supplements
Comparison: no nutrit ional supplements












Primary cure No trials met the inclusion criteria. Thus, there is
no data for this outcome
- (0 RCTs) - -
Def init ive cure No trials met the inclusion criteria. Thus, there is
no data for this outcome
- (0 RCTs) - -
Treatment complet ion No trials met the inclusion criteria. Thus, there is
no data for this outcome
- (0 RCTs) - -
Self -reported recovery
f rom illness or resolu-
t ion of symptoms
No trials met the inclusion criteria. Thus, there is
no data for this outcome
- (0 RCTs) - -
Weight gain, increased
skinfold thickness, or
other measures of lean
or total mass, or growth
in children
No trials met the inclusion criteria. Thus, there is
no data for this outcome
- (0 RCTs) - -
Adverse outcomes No trials met the inclusion criteria. Thus, there is
no data for this outcome
- (0 RCTs) - -












































































































GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect














































































































B A C K G R O U N D
Description of the condition
The leishmaniases are a group of diseases caused by protozoan
parasites of the genus Leishmania. The parasite is transmitted by
bites of the insects from the Diptera family, genus Phlebotomus
and Lutzomya (also called sandflies), which are infected with the
Leishmania parasite.
Leishmaniasis can have many different clinical presentations, in-
cluding subclinical (or unapparent) infection, localised skin lesions
(solitary or limited cutaneous leishmaniasis), and disseminated in-
fection (cutaneous, mucosal, or visceral leishmaniasis (VL)), which
are associated with a variety of signs, symptoms, and degrees of
severity (Murray 2005). For the purpose of this Cochrane Review,
we focused solely on VL.
VL is considered a “tool-deficient” disease in terms of control,
which means that the available tools for the control of the disease
are inadequate for scaling up campaigns, can be very costly, and
require specially-trained staff and strong logistical support (WHO/
The Carter Center 2008).
Clinical features of VL
The amastigote form of the Leishmania parasite attacks the retic-
uloendothelial system of naive people. This lowers the immunity
of the infected person and causes limited infections that either
spontaneously resolve or progress over weeks and months with
persistent fever, anaemia, cough, abdominal pain, diarrhoea, en-
largement of the liver and spleen (hepatosplenomegaly), weight
loss, bleeding from the nose (epistaxis) due to decreased platelets
(thrombocytopenia), depleted blood counts (pancytopenia), sus-
ceptibility to secondary infections, and also to death if disease is
untreated. Signs of malnutrition (oedema, skin, and hair changes)
develop as the disease progresses (Murray 2005; WHO 2010).
Specific disease symptoms may differ from region to region; for ex-
ample, darkening of the skin of the face, hands, feet, and abdomen
is typically found in patients of the Indian subcontinent (the Hindi
name, kala-azar, means ’black fever’ or deadly fever). Also, if the
patient’s immune system is reconstituted, VL may evolve to a skin
condition known as post-kala-azar dermal leishmaniasis (PKDL;
Zijlstra 2003).
VL and immunosuppression
VL is also an opportunistic infection in people living with HIV
or other immunosuppressed patients (Alvar 2008; van Griensven
2014). Active VL may represent a relapse (recurrence six to 12
months after apparently successful treatment) or late reactivation
of a subclinical or previously-treated infection. Reactivation can
be spontaneous, but can also occur due to a reduction in T-cell
(CD4) number or function due to immunosuppressive drugs and
in people living with advanced HIV disease (Alvar 2008).
The increased prevalence of HIV in the last three decades has made
the treatment and control of leishmaniasis more important, as the
two infections are closely associated in many parts of the world,
and issues of prevention and control are of global public health
importance (Alvar 2008).
Causes and impact
The estimated global annual incidence of VL is 0.2 to 0.4 mil-
lion people, and 90% of the cases occur in just six countries: In-
dia, Bangladesh, Sudan, South Sudan, Ethiopia, and Brazil (Alvar
2012). VL causes an estimated 20,000 to 40,000 deaths annually
(a rate surpassed among parasitic diseases only by malaria), and
357,000 disability-adjusted life years lost (DALYs), which places
leishmaniasis ninth in a global analysis of infectious diseases (Hotez
2004). Incidence of VL is sharply declining in the Indian subcon-
tinent due to various reasons, including the natural trend and the
kala-azar national elimination program (NVBDCP Programme
2017).
VL may be endemic, sporadic, or epidemic. In areas endemic for
VL, the disease tends to be relatively chronic, and children, in par-
ticular, are affected. Sporadic VL may occur in non-native people
of any age who enter an endemic area. In epidemic VL, people
of all ages are susceptible, except those who acquired immunity
previously. Acute cases of the disease can occur, and mortality is
usually high.
In the Old World, VL is caused by Leishmania donovani and Leish-
mania infantum parasite species. Most infections are asymptomatic
(almost 90%), and longitudinal studies have shown that depend-
ing on host condition (malnutrition, immune suppression, and
others), the infected person may develop clinical disease (Badaró
1986; Ferreira 2018). In Old World endemic areas, the most af-
fected age group has traditionally been children aged between one
and four years (Harhay 2011). However in Europe, since the ad-
vent of HIV infection and increased use of immunosuppressive
therapies for transplantation and chemotherapy, about half of the
VL cases occur in adults (Carrillo 2015). Nevertheless, in endemic
areas of East Africa and India, the highest incidence remains in
children and young adults (Alvar 2012; Harhay 2011). PKDL oc-
curs in areas endemic for L. donovani, but is more common in
East Africa and in Asia, where up to 50% in East Africa and up
to 10% to 20% of VL patients in Asia will develop the condition
after treatment (Zijlstra 2003; Zijlstra 2017).
In the New World, the etiological agent is L. infantum. Most cases
occur in children under 10 years of age, but adults are also fre-
quently affected because of recent introduction of the organism.
PKDL is extremely rare. Longitudinal follow-up has shown that
some people remain asymptomatic or recover spontaneously from
mild disease, while others with these conditions eventually develop
clinical VL. Risk factors for progression to VL include malnutri-
tion and other infectious diseases (Badaró 1986; Ferreira 2018).
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Diagnosis of VL
Clinical diagnosis
The clinical characteristics of VL are: persistent fever (more than
two weeks) not due to malaria, tuberculosis, or other infections
(unresponsive to a course of antibiotics); splenomegaly; and weight
loss. In people living with HIV, the clinical features of VL may be
atypical. The isolated or combined presence of anaemia, leukope-
nia, thrombocytopenia, or polyclonal hypergammaglobulinaemia
reinforces the clinical suspicion but lacks diagnostic accuracy.
Therefore, Leishmania-specific laboratory tests are required for di-
agnostic confirmation.
Parasitological diagnosis
Parasitological confirmation should be based on microscopy and
demonstration of the parasite through morphological identifica-
tion or cultured parasites from aspirates of spleen, bone marrow, or
lymph nodes (the later mainly valid in East Africa), or molecular
biological methods, such as polymerase chain reaction (PCR), or
both.
Serological diagnosis
Serological confirmation should be based on the use of specific
anti-Leishmania antibodies. Among various options, the most fea-
sible and recommended technique is rk39-based immuno chro-
matographic test, which in case of doubtful results, should be
combined with a second serological test, like direct agglutina-
tion test (DAT), immunofluorescence antibody test (IFAT), or
enzyme-linked immunosorbent assay (ELISA; (Boelaert 2014;
WHO 2010)).
All serological tests suffer from two limitations. First, specific an-
tibodies remain detectable up to several years after cure of the in-
fection. Therefore, relapse cannot reliably be diagnosed by serol-
ogy. Second, a proportion of healthy people living in VL-endemic
areas with no history of VL may show low positive titers for anti-
leishmanial antibodies, due to asymptomatic infection or cross-re-
actions with other diseases. Therefore, antibody-based tests must
always be used in combination with a standardized clinical case
definition for VL diagnosis (WHO 2010).
Treatment of VL
Treatment should be given only after confirmation of the disease.
The extent of concomitant infection should be ascertained, as this
may influence the choice of therapy or supportive treatment. In
many cases, supportive treatment and patient stabilization, for
example rehydration or nutritional supplementation, are essential
before starting the therapy, and may also decrease drug toxicity.
For the past seven decades, pentavalent antimonials have been
the standard first-line treatment for people with VL, and ampho-
tericin B deoxycholate and pentamidine have been the second-
line treatment. In the past 10 years, lipid formulations of ampho-
tericin B, miltefosine, and paromomycin have been approved for
VL treatment. The risk of developing resistance to monotherapy
is the main reason combined medications are recommended (van
Griensven 2014).
Ideally, VL treatment should cure the patient, reduce the risk for
relapse and for PKDL, and avoid the development of resistance.
Successful therapy improves the general condition and weight of
the person, resolves fever, causes regression of splenomegaly, and
recovery of normal blood counts. An initial cure can be declared
if there is clinical improvement at the end of treatment. Complete
regression of splenomegaly may take several months. A good in-
dicator of definitive cure is the absence of clinical relapse at six
months, although relapses can occur later.
Poor prognostic factors in response to VL treatment are age over
45 years (in Africa), malnutrition, renal and hepatic comorbidity,
concomitant infections, such as pneumonia, tuberculosis, or HIV
infection, or other immunosuppressive conditions (WHO 2010).
Description of the intervention
Nutrition interventions can broadly be divided into macronutri-
ents (carbohydrates, protein, and fat), and micronutrients (essen-
tial vitamins and trace elements).
Macronutrients
The energy requirements of a 70 kg adult male to maintain body
weight and composition are approximately 2550 kilocalories (kcal)
per day, ideally consumed as 55% carbohydrate, 15% protein, and
30% fat (FAO/WHO/UNICEF 2001).
If it was shown that people with active VL required additional
macronutrients, these could be purchased and consumed by the
patient simply by following nutritional advice. However, leishma-
niasis has strong links with poverty, and usually affects people from
the poorest segments of the population. Therefore, in many situ-
ations, especially in resource-limited settings, the person may not
be able to acquire this additional food, due to economic hardship
or local food insecurity (Alvar 2006). In these situations, health-
care services might provide increased nutrients through free provi-
sion of meals, take-home rations, or specific high-energy supple-
ments. United Nations International Children’s Emergency Fund
(UNICEF) provides therapeutic feeding to children under five
years of age with VL, but only if they suffer from severe, acute
malnutrition. In East African countries, in which up to 40% of the
VL patients are malnourished, only non-governmental organiza-
tions (NGOs) can supplement food as part of their VL treatment
programmes. Moreover, although medicines for the treatment of
people with VL are given free of cost for VL patients treated by
the Ministry of Health within the national programmes, patients
must pay for concomitant treatments, diagnostics, and in-hospi-
talizations costs, including food.
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Micronutrients
The daily micronutrient requirements for individuals vary greatly
by age and gender (Food and Nutrition Board 2006).
These requirements can be gained from the consumption of a
healthy and varied diet, or through pharmaceutical supplementa-
tion as tablets, capsules, or powders. Any additional requirements
could be gained through increased consumption following dietary
advice, or through pharmaceutical provision via the health service.
In trials of macronutrient and micronutrient interventions, the
following two important factors should be noted.
• The intervention is a supplement and does not represent
the total daily intake of that nutrient.
• Any benefit derived from the intervention is likely to be
dependent on the initial nutritional status of the patient.
In order to accurately interpret the data, it is therefore essential
to consider both the baseline (before starting the intervention)
nutritional status, and the overall nutritional intake of the patients.
How the intervention might work
Malnutrition takes many forms, but in the regions affected by VL,
it most commonly refers to inadequate protein and energy intake
(protein energy malnutrition, or PEM), in association with mul-
tiple micronutrient deficiencies. These two nutritional problems
are one of the major health burdens in developing countries.
As already described, VL is mainly found among poor commu-
nities, in which diets are frequently inadequate to meet the rec-
ommended daily requirements. Malnutrition is also more pro-
nounced in individuals with infection or advance disease, as a con-
sequence of reduced nutrient intake, increased nutritional needs,
and excessive losses due to diarrhoea, malabsorption, and parasitic
infections. In these communities, a high prevalence of poor diet
and infectious disease regularly converges into a vicious cycle.
Observational studies have suggested that both PEM and mi-
cronutrient deficiencies may hasten the progression of leishmani-
asis infection (Anstead 2001; Cerf 1987; Collin 2004; Dye 1993),
and that VL worsens malnutrition (Luz 2001; Van Weyenbergh
2004). The leishmaniasis infection and malnutrition ’vicious cy-
cle’ of immune dysfunction, infectious disease, and malnutrition
has already been described (Malafaia 2009; Serafim 2010).
Harhay 2011 analysed the nutritional data of 29,750 VL patients
from six of the most endemic foci of VL (Brazil, India, Nepal,
Sudan, South Sudan, and Uganda). In some of the study sites,
up to 25% of them had severe acute malnutrition and 40% were
underweight. This study also noted that supplementary and ther-
apeutic feeding interventions for VL patients were generally in
place in treatment sites run by NGOs, but were often lacking in
governmental centres.
Malnutrition and VL are interconnected health problems. It is
difficult to evaluate to what extent malnutrition is either a risk
factor for, or the result of, VL.
Therefore, the inclusion of nutrient supplementation in the treat-
ment of active VL could improve morbidity and mortality out-
comes of the disease, by doing the following.
• Improve VL treatment outcomes by restoring cell-mediated
immunity, increasing the individual’s ability to fight the
infection, and hastening recovery from the illness.
• Promote nutritional recovery with increased weight gain in
adults, and weight gain and growth in children.
Notably, pathogens such as Leishmania also require certain mi-
cronutrients for their own metabolism, and greater availability of
these nutrients through supplementation could encourage their
growth. There is some evidence for this regarding vitamin C and
vitamin E supplementation (Garg 2004), and pantothenic acid (vi-
tamin B5) supplementation (Actor 1960). Therefore, nutritional
interventions cannot be considered entirely benign.
Why it is important to do this review
There is no evidence-based guidance on food provision or sup-
plementation for adults or children being treated for VL, with
or without concurrent HIV infection. This Cochrane Review at-
tempted to assess the evidence for the effectiveness of different
food and nutritional supplements in helping people to recover
from VL, and to highlight where more research might be needed.
O B J E C T I V E S
To assess the effects of oral nutritional supplements in people being
treated with anti-leishmanial drug therapy for VL.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered the following study designs, with allocation at ei-
ther the individual or cluster level.
• Randomized controlled trials (RCTs): a trial in which the
trial investigator prospectively allocates each participant (or
group of participants) to an intervention or to a control arm
using a process of random allocation (for example, random
number generation or coin flips).
• Quasi-randomized controlled trials (quasi-RCTs): a non-
randomized trial in which the investigator prospectively allocates
each participant (or group of participants) to an intervention or
to a control arm using a process that attempts, but does not
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achieve, true randomization (for example, alternation of
allocation, birth dates, or weekdays).
• Non-randomized controlled trials (NRCTs): a non-
randomized study in which the investigator prospectively
allocates each participant (or group of participants) to an
intervention or to a control group (or more) using a process that
is clearly not random (for example, allocation by judgement of
the clinician, or by preference of the participant).
Types of participants
We considered people of all ages, with or without human immun-
odeficiency virus (HIV) infection, and being treated for VL.
Types of interventions
Intervention
We considered any oral nutritional supplement given in addition
to any anti-leishmanial drug treatment. We excluded trials that
assessed tube feeding or parenteral nutrition, as well as trials that
assessed dietary advice alone, without the actual provision of sup-
plements.
Control
No nutritional intervention, placebo, or dietary advice alone.
Types of outcome measures
Primary outcomes
• Primary cure (clinical and parasitological improvement
after treatment), defined as the absence of parasites at the end of
treatment, resolution of clinical signs and symptoms of VL
(defervescence, weight gain, and decrease in spleen size), and
absence of clinical signs attributable to PKDL.
Secondary outcomes
• Definitive cure, defined as confirmed cure at the end of
treatment, with no VL signs or symptoms, or clinical signs of
PKDL, which require rescue treatment, within six months of
follow-up.
• Treatment completion.
• Self-reported recovery from illness or resolution of
symptoms.
• Weight gain, increased skinfold thickness, or other
measures of lean or total mass.
• In children, any measure of growth: improvement of height
for age, weight for height, weight for age, body mass index
(BMI) for age, or any other nutritional indicator used as baseline
measure at start of treatment.
Adverse outcomes
• No cure, defined as any of the following situations (or a
combination among them): no clinical improvement during
treatment or after treatment completion, no parasitological cure
(parasitology remains positive), or need of rescue medication.
• Death from any cause.
• Relapse, defined as a patient who had an initial cure, but
presented with VL signs and symptoms after treatment, up to
six-month follow-up, patient required rescue medication.
Search methods for identification of studies
We attempted to identify all relevant studies, regardless of lan-




We searched the following databases for relevant studies, us-
ing the search terms and strategies detailed in Appendix 1: the
Cochrane Infectious Diseases Group (CIDG) Specialized Regis-
ter (12 September 2017); the Cochrane Central Register of Con-
trolled Trials (CENTRAL; 2017, Issue 9), in the Cochrane Li-
brary (12 September 2017); MEDLINE (PubMed, 1966 to 12
September 2017); Embase OVID (1980 to 12 September 2017);
LILACS (Latin American and Caribbean Health Science Infor-
mation database; 1982 to 12 September 2017).
On 17 September 2017, we also searched the WHO Interna-
tional Clinical Trials Registry Platform (ICTRP; www.who.int/
ictrp/en/); and ClinicalTrials.gov (clinicaltrials.gov), using leish-
mania, leishman*, and leishmaniasis as search terms.
Searching other resources
Conference proceedings
We searched the following conferences proceedings for relevant
abstracts.
• 1st World Congress on Public Health, 2006 September 20-
28; Barcelona, Spain.
• 2nd World Congress on Public Health, 2010 September 23-
25; Oporto, Portugal.
• 3rd World Congress on Public Health, 2014 November 9-
11; Las Palmas de Gran Canaria, Spain.
• 18th International Nutrition Congress, 2005 September
20-23; Durban, South Africa.
• 19th International Nutrition Congress, 2009 September 4-
9; Bangkok, Thailand.
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• 20th International Nutrition Congress, 2013 September
15-20; Granada, Spain.
• 3rd World Congress on Leishmaniasis, 2005 April 10-15;
Palermo, Italy.
• 4th World Congress on Leishmaniasis, 2009 February 3-7;
Lucknow, India.
• 5th World Congress on Leishmaniasis, 2013 May 13-17;
Pernambuco, Brazil.
• 6thWorld Congress on Leishmaniasis, 2017 May 16-20;
Toledo, Spain.
Consultative meetings reports
We screened the following WHO reports: WHO 2010; WHO
2013; WHO 2014a; WHO 2014b; WHO 2014c; WHO 2014d;
WHO 2014e; WHO 2015a; WHO 2015b; WHO 2016a; WHO
2016b; WHO 2016c; WHO 2016d; WHO 2017a; WHO 2017b;
WHO 2017c; and WHO 2017d.
Researchers
We contacted key authors in the field and the authors of simi-
lar systematic reviews. We had planned to contact the authors of
studies included in the review, and of ongoing studies identified
in the different clinical trials registration systems.
Companies
On the 27 November 2017, we contacted the following companies
for unpublished and ongoing trials: AkzoNobe, DSM Nutritional
Products, Nestle, Nutergia, and Taiyo International.
Reference lists
We also checked the reference lists of key documents and existing
reviews (Bush 2017; Chappuis 2007; Cheeran 2010; Elmahallawy
2015; Freitas-Junior 2012; Olliaro 2005).
See the ‘Differences between protocol and review’ section.
Data collection and analysis
Selection of studies
At least two review authors (EC, JA, JLA, and SSgB) indepen-
dently screened all citations and abstracts identified by the search
strategy to identify potentially eligible studies. We obtained the
full-text articles of potentially eligible studies. At least two review
authors (EC, JLA, and SSgB) independently assessed these arti-
cles for inclusion, using a predefined eligibility form, based on the
inclusion criteria. We had planned to contact the study authors
for clarification in the event that it was unclear whether a trial
was eligible for inclusion in the review. If there was no consensus
between the two review authors involved in the screening of titles
and abstracts, or in the assessment of the full-texts, we consulted a
third review author. We used Covidence to implement the selec-
tion process (Covidence 2017).
We excluded studies that did not meet the inclusion criteria, and
documented the reasons for the exclusion of the full texts assessed.
Data extraction and management
We foresaw that at least two review authors (EC, JLA, or MH)
would independently extract data from each included study, using
tailored and pre-tested data extraction forms. We had planned to
extract data on study design, participant characteristics, interven-
tions, and outcomes.
For dichotomous data, we had planned to extract the number
of participants with at least one event, and the total number of
participants in each treatment arm. For continuous outcomes, we
had planned to extract the number of participants, the arithmetic
mean, and the standard deviation (SD) for each group. If trial
authors had reported median values, we had planned to extract
ranges or interquartile ranges.
If the included trials had reported time-to-event outcomes, we had
planned to extract the estimates of the log hazard ratio (HR) and its
standard error (SE). If SEs had been unavailable, we had planned
to extract alternative statistics, such as confidence intervals (CIs)
or P values.
In cases of skewed continuous data, we had planned to extract
geometric means, where presented by the study author.
For cluster-RCTs that adjust for clustering, the ideal information
to extract would have been a direct estimate of the required ef-
fect measure with its CI, or measure of variation. In addition, for
cluster-RCTs that did not adjust for clustering, we had planned to
extract the average size of each cluster and the intra-cluster corre-
lation coefficient (ICC), and we had planned to adjust these data
using available methods, such as the effective sample size or the
inflated variance (Higgins 2011). If the ICC had been unknown,
we would have tried to make an estimation from external sources,
such as trials with similar cluster sizes and features. Once we had
adjusted trials, we had planned to combine the data in a meta-anal-
ysis. If we had been unable to adjust these trials, we had planned
to exclude these data from the meta-analysis.
Assessment of risk of bias in included studies
Two review authors (EC, MH, or JLA) had planned to indepen-
dently assess the risk of bias of each included RCT using the
Cochrane ’Risk of bias’ assessment tool (Higgins 2011). We had
planned to assess the following six components for each included
trial: sequence generation, allocation concealment, blinding, in-
complete outcome data, selective outcome reporting, and other
biases. For each of these components, we had planned to assign
a judgment on the risk of bias of either ’yes’ (low risk of bias),
’no’ (high risk of bias), or ’unclear’ (unclear risk of bias). We had
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planned to contact the trial authors for clarification if any of the
six components were unclear, or not stated in the report. We had
planned to record the results in the ’Risk of bias’ tables in Review
Manager 5 (RevMan 5), and to summarize the findings as a ’Risk
of bias’ table or graph (RevMan 2014).
To assess the risk of bias of the non-randomized trials eligible for
this review (that is, quasi-RCTs and non-randomized-RCTs) we
had planned to use the ROBINS-I tool (Sterne 2016a), and follow
the guidance detailed in Sterne 2016b (see the ‘Agreements and
disagreements with other studies or reviews’ section).
Measures of treatment effect
We had planned to compare dichotomous outcomes using risk
ratios (RR) and their 95% CIs. For continuous data reported as
arithmetic means and SDs, we had planned to combine them using
the mean difference. Where included studies reported continuous
data using geometric means, we had planned to combine these
data on the log scale, using the generic inverse variance method,
and report them on the natural scale; we had planned to report
the medians and ranges in a table. We had planned to present all
results with 95% CIs.
Unit of analysis issues
For trials that included more than two comparison groups, we had
planned to split and analyse them as individual pair-wise compar-
isons.
If included studies had reported count data, we had planned to
extract the total number of events in each group, and the total
amount of person-time at risk in each group. We had planned
also to record the total number of participants in each group. If
this information had been unavailable, we had planned to extract
alternative summary statistics, such as rate ratios and CIs, if avail-
able. For studies presenting count data as dichotomous outcomes,
we had planned to extract the number of participants in each in-
tervention group, and the number of participants in each inter-
vention group who experienced at least one event.
Dealing with missing data
We had planned to obtain missing data from the authors of the
included trials. Where possible, we had planned to extract data to
allow an intention-to-treat (ITT) analysis, in which we would have
analysed all randomized participants in the groups to which they
were originally assigned. If there had been any discrepancy in the
number of participants randomized and the numbers analysed in
each treatment group, we had planned to calculate the percentage
lost to follow-up in each group, and report this information. If
people lost to follow-up had exceeded 10% for any trial, we had
planned to assign the worse outcome to those lost to follow-up
for dichotomous outcomes (except for the outcome of death), and
assess the impact of this in sensitivity analyses, with the results of
completers.
For continuous data with missing SDs, we had planned to either
calculate these SDs from other available data, such as SEs, or to
impute them, using methods suggested in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We would
not have made any assumptions about losses to follow-up for con-
tinuous data, and we had planned to analyse the results for those
participants who had completed the trial.
Assessment of heterogeneity
We had planned to assess heterogeneity between the included tri-
als by visual examination of the forest plot to check for overlap-
ping CIs, using the Chi² test for heterogeneity with a 10% level
of significance, and the I² statistic. We had planned to use an I²
statistic value of 50% or greater to denote significant heterogene-
ity. If this value had been substantial (75% or greater), we would
not have attempted data synthesis if we couldn’t explain hetero-
geneity by clinical or methodological features of the trial, or by
subgroup analyses (see the ‘Subgroup analysis and investigation of
heterogeneity’ section).
Assessment of reporting biases
We had planned to assess the likelihood of publication bias by
examining a funnel plot for asymmetry due to small study effects,
provided that there were at least 10 included trials.
Data synthesis
We had planned to synthesize dichotomous data using pooled and
weighted risk ratios (RR). We had planned to combine continu-
ous data, summarized by arithmetic means and SDs, using mean
differences. If study authors had summarized continuous data by
using geometric means, we had planned to combine them on the
log scale, using the generic inverse variance method, and to report
them on the natural scale. We had planned to compare count data
using rate ratios, when the total number of events in each group
and the total amount of person-time at risk in each group was
available, by RR if data had been presented in dichotomous form,
or mean difference if data were presented in continuous forms.
We had planned to combine the HRs from survival data on the
log scale, using the inverse variance method, and to present these
data on the natural scale.
Subgroup analysis and investigation of heterogeneity
We had planned to use a fixed-effect model to synthesize data when
there was no heterogeneity. We had planned to combine the trials
using a random-effects model when heterogeneity was present, but
not substantial (I² statistic greater than 50%, but less than 75%), or
when it could not be explained by subgroup analyses, or by clinical
or methodological features of the trials and the participants. If
we had found substantial heterogeneity, or substantial differences
across the trials in clinical or methodological features, we had
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planned to present the trials in a forest plot, but not combine
them in a meta-analysis. If data had permitted, we had planned to









We had planned to undertake sensitivity analyses if trials reported
dropout rates of 10% or greater, to ascertain differences in out-
comes with ITT analyses, and analyses of completers.
For included cluster-RCTs, we had planned to follow the CIDG
cluster-RCT
guide checklist (cidg.cochrane.org/sites/cidg.cochrane.org/files/
public/uploads/cluster randomised trials guide feb2010.doc). If
study authors had estimated ICC, we had planned to perform sen-
sitivity analyses by excluding trials that did not originally adjust
for clustering, to see if the results of the meta-analysis changed.
When study authors did not report ICC, and we couldn’t calcu-
late it manually to give an approximate value, we had planned to
perform sensitivity analyses using a range of estimates for the ICC,
to see if clustering could influence the individual trial’s result.
R E S U L T S
Description of studies
Results of the search
Following removal of duplicates, the search strategy of the elec-
tronic databases to 12 September 2017 generated 193 records. We
examined the titles and abstracts of these records to assess their
potential relevance, and we subsequently retrieved six full-texts for
further examination. We did not identify any studies that met the
eligibility criteria.
We did not find any eligible study, either completed or ongoing,
by searching trial registries. We found no references by checking
the abstracts of relevant conferences or meetings, reference lists
of key documents, or through personal contact with experts in
the field or nutritional supplement companies. See the study flow
diagram, which follows the template described in the PRISMA
statement (Figure 1; Liberati 2009).
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Figure 1. Study flow diagram
Included studies
We found no eligible studies for this review, neither completed
nor ongoing.
Excluded studies
We excluded all six records after full-text assessment (Aruoma
2006; Croft 1985; Diro 2015; Duke 2011; Maciel 2014; Thakur
2010). We summarized the reasons for their exclusion in the flow
diagram (Figure 1) and in the ’Characteristics of excluded studies’
table.
We excluded NCT01069198, an ongoing trial on the efficacy of
a combination of anti-helminth, and vitamin A, zinc, and iron
supplementation in preventing active VL among individuals with
asymptomatic VL. The control group of this trial received placebo
without an active treatment for VL (for a study to be eligible both
study groups had to receive active treatment for VL).
Risk of bias in included studies
No studies met the eligibility criteria, so we could not assess risk
of bias.
Effects of interventions
See: Summary of findings for the main comparison Nutritional
supplements versus no nutritional supplements for people who are
being treated for active visceral leishmaniasis (VL)
We did not find any trial that assessed the effects of oral nutri-
tional supplements in people who were being treated with anti-
leishmanial drug therapy for VL. See ‘Summary of findings’ table
1 (Summary of findings for the main comparison).
D I S C U S S I O N
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Summary of main results
We did not find any eligible studies, either completed or ongoing,
for this review. Consequently, we could not determine the effects
of oral nutritional supplements in people who were being treated
with anti-leishmanial drug therapy for VL.
Overall completeness and applicability of
evidence
Completeness of the evidence
No trials met our inclusion criteria. Thus, the evidence base for
the effects of oral nutritional supplements in people being treated
with anti-leishmanial drug therapy for VL is incomplete.
We were surprised by the lack of studies that met our inclusion cri-
teria, and by the low number of records generated by the searches
in electronic databases (only 193 references after eliminating du-
plicates), as the topic area is not immature, and the leishmaniasis
infection and malnutrition ‘vicious cycle’ of immune dysfunction,
infectious disease, and malnutrition has already been described
(Malafaia 2009; Serafim 2010). However, the lack of studies may
be explained by several factors.
First, leishmaniasis is considered a neglected disease, that is, a
group of diseases characterised by their association with poverty,
and their proliferation in tropical environments (Alvar 2006;
WHO 2007). Therefore, resources allocated to the study of the
disease, or implementation of programmes to combat related fac-
tors, have been scarce compared to other diseases, which can help
to explain the low number of references retrieved in the search
strategy of this review (WHO 2012).
Second, we had planned to disentangle the effects of nutritional
supplements given in addition to any anti-leishmanial drug treat-
ment. Thus, we excluded studies that did not consider the nutri-
tional supplementation as the only difference between study arms.
That is, for a study to be included, the anti-leishmanial drug treat-
ment had to be the same in the study arms, and no other condition
except for the nutritional supplementation could differ between
them.
Third, the methodological challenges associated with the evalu-
ation of nutritional interventions may hamper the realization of
these trials. As an example, nutritional interventions are usually
implemented in addition to other interventions, which makes
them ‘complex interventions’, that is, interventions with several
interacting components. Complex interventions present several
special problems for evaluators, in addition to the practical and
methodological difficulties that any successful evaluation must
overcome (MRC 2008). Moreover, conducting RCTs in the con-
texts where VL and malnutrition are highly prevalent, such as
South Sudan, is challenging.
Fourth, we restricted our review to controlled clinical trials, either
randomized or not. Therefore, we excluded observational studies,
which are common in the field of nutrition research, because of
an inherently high risk of selection and detection biases (Ortiz-
Moncada 2011).
Applicability of the evidence
Applicability of the evidence is the assessment of whether the find-
ings of a review can be applied in a particular context or popula-
tion (Burford 2013). We could not assess the applicability of the
evidence of this review, as we did not find any eligible studies.
Quality of the evidence
We identified no relevant studies that met the inclusion criteria of
this review. Thus, we were unable to comment on the certainty of
the evidence for this clinical question.
Potential biases in the review process
Search methods for identification of studies
We performed searches as extensively as possible, in order to re-
duce the risk of publication bias, and to identify as much relevant
information as possible. The Information Specialist of the CIDG
carefully designed the searches, without any language or date of
publication restrictions. However, we may have lost some eligible
studies, as the risk of publication bias in the field of nutrition re-
search might be even higher than in drug research (Chartres 2016).
On the other hand, we may have missed individuals or organi-
zations that have conducted eligible RCTs, so we may not have
identified relevant RCTs.
‘Summary of findings’ tables
In our protocol, we did not plan to create ‘Summary of findings’
tables, therefore, we chose the outcomes for the ‘Summary of find-
ings’ tables after the protocol publication. However, we think that
the outcomes we chose are relevant to support informed decisions.
Agreements and disagreements with other
studies or reviews
As there are no included studies in this review, we were unable
to locate any evidence that could be compared with other stud-
ies. We found no experimental studies conducted in humans on
the topic, but there was a review that assessed the role of protein-
energy malnutrition as a risk factor for VL, confirming malnutri-
tion as a major determinant of both progression and severity of
the disease (Malafaia 2009). However, this review did not assess
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the effect of nutrient supplementation on VL patients. The exist-
ing experimental studies conducted in animal models have yielded
conflicting results on nutritional components of the diets and the
progression of VL in infected animals. More specifically, in terms
of a) macronutrients and protein supplementation (Actor 1958;
Anstead 2001; Ritterson 1949), and b) micronutrient supplemen-
tation such as vitamins (A, B-complex, and E) or minerals (iron
and copper; Actor 1958; Actor 1960; Anstead 2001; Garg 2004).
Some of these studies found an antagonistic relationship between
the nutrient supplementation and the proliferation of the infec-
tion, while others found a synergistic association. Only in relation
to the supplementation of vitamin C, zinc, and flavonoids, were
the results consistent with the potential improvement of the pre-
vention and progression of VL (Anstead 2001; Garg 2004; Mittra
2000; Van Weyenbergh 2004).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found no studies, either completed or ongoing, that assessed
the effects of oral nutritional supplements in people with visceral
leishmaniasis (VL), treated with anti-leishmanial drug therapy.
Thus, we cannot conclude on the impact of these interventions
on primary cure of VL, definitive cure of VL, treatment com-
pletion, self-reported recovery from illness or resolution of symp-
toms, weight gain, increased skinfold thickness, or other measures
of lean or total mass, or growth in children.
The absence of evidence should not be interpreted as the evidence
of no effect for nutritional supplements in people under VL treat-
ment. It means that eligible research for this review was not iden-
tified.
Implications for research
This is an ’empty review’, that is, a review that has no included
studies. This highlights the need for rigorous studies to determine
the effects of oral nutritional supplements in people with VL, who
are receiving anti-leishmanial drug therapy.
Randomized controlled trials (RCT) testing the effect of a specific
nutrient are essential, as the randomized design is the only one
that is able to demonstrate a causal relationship between a dietary
change and health outcomes (Ioannidis 2016; Jakobsen 2013;
Laville 2017; Maki 2014). However, RCTs of nutrients encounter
additional barriers to those that affect the traditional drug RCTs
(Laville 2017).
Table 1 details the nature of further research that would be most
desirable, according to the ’Evidence - Population(s) - Intervention
- Comparison - Outcomes - Time stamp’ (EPICOT) format (
Brown 2006).
Future RCTs should be rigorous in design and delivery. They
should be adequately reported, which would enable appraisal
and interpretation of results. Trials should be reported according
to relevant reporting guidelines, such as: CONSORT statement
(Schulz 2010); CONSORT extension for cluster-randomized tri-
als (Campbell 2012); TIDieR checklist (Hoffmann 2014); or the
reporting guidelines for health equity concerns in RCTs (Welch
2017). The Equator Library for health research reporting should
be searched for pertinent reporting guidelines (Equator Network
2017).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aruoma 2006 Participants without VL.
Croft 1985 In vitro study that did not include humans.
Diro 2015 Study did not evaluate the effects of nutritional supplement
Duke 2011 Study design: not a controlled-clinical trial.
Maciel 2014 Participants with VL not being treated for VL.
NCT01069198 The control group received placebo rather than an active treatment for VL
Thakur 2010 Study did not evaluate the effects of nutritional supplement
Abbreviations: VL: visceral leishmaniasis.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Research recommendation
What are the effects of nutritional supplements in patients being treated for active visceral leishmaniasis (VL)?
Evidence: we found no eligible studies for this systematic review.
Elements Proposal Comments
Population People being treated for VL • Include all relevant participant
groups, such as people with HIV.
• Large, adequately powered trial.
• Preferably multi-centre trial, in order
to achieve adequate sample size (Laville
2017).
• Stratify allocation according to age
and basic nutritional status, to enable
robust a priori subgroup analyses.
Intervention Oral nutritional supplement • If only a nutrient is tested, a placebo
can be easily used, and a blinded RCT can
be conducted (Laville 2017).
• The study should be planned with
few interventions, to allow the effect of
the micronutrient to be evaluated.
• Provide details of all the
interventions and co-interventions
undertaken, of their compliance and their
acceptability (Hoffmann 2014; MRC
2008).
• In order to disentangle the effects of
the nutrient on the outcome measure, the
co-interventions must be similar in all
study groups.
• Compliance can be checked by
counting pills, and possibly by assessing
the nutrient concentration or related
functions (Laville 2017).Comparison Placebo
Outcomes Relevant outcomes for key stakeholders de-
fined, measured, collected, and reported in
an objective, reliable, accurate, and action-
able way
• To our knowledge, there is no ’core
outcome set’ (COS)a developed with a
rigorous methodology for RCTs of
nutritional supplements.
• COS for RCTs of nutritional
supplements should be developed with
the method proposed in the COMET
Handbook (Williamson 2017).
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Table 1. Research recommendation (Continued)
• Blinding of patients, care givers and
outcome assessment should be ensured
with the use of placebo as a control group.
The use of objective outcomes that are less
susceptible to bias can also minimize the
risk of detection bias (Lin 2012).
• Relevant harms related to the use of
nutrients should be specified beforehand,
and should be assessed (Ioannidis 2004).
Study type RCT Clus-
ter-RCTs (RCTs that randomize groups
(clusters) rather than individuals) have sev-
eral advantages compared to individual-
RCTs (López-Alcalde 2015). For example,
they may be less costly and time-consum-
ing, as they simplify the logistics of imple-
mentation (Smith 2008); they control for
confounding (Safdar 2008), and minimize
treatment contaminationb between inter-
vention and control participants (Hayes
2000); they are better for measuring the
overall group effect of an intervention, and
for judging effectiveness (Hayes 2000), that
is, the extent to which a specific inter-
vention, when used under ordinary cir-
cumstances, does what it is intended to
do (Cochrane 2017). Moreover, they have
broader generalizability. For example, clus-
ter-RCTs minimize the Hawthorne effect,
which is the effect on the people being stud-
ied (usually positive or beneficial), of being
under study (Porta 2008).
Abbreviations: COS: core outcome set; HIV: human immunodeficiency virus; RCT: randomized controlled trial; VL: visceral leish-
maniasis.
aCore outcome set: agreed standardized set of outcomes that should be measured and reported in all trials for a specific clinical area
(Williamson 2012).
bContamination: in a controlled trial, contamination is the inadvertent application of the intervention being evaluated to people in
the control group, or the inadvertent failure to apply the intervention to people assigned to the intervention group (Cochrane 2017).
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A P P E N D I C E S
Appendix 1. Search strategy
Search set CIDG SRa CENTRAL MEDLINEb Embaseb LILACSc WHO ICTRP ClinicalTri-
als.gov
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(Continued)
10 Food - - 5 or 6 or 7 or 8
or 9
Food - -
11 5 or 6 or 7 or 8
or 9 or 10
- - 4 and 10 5 or 6 or 7 or 8
or 9 or 10
- -
12 4 and 10 - - - 4 and 10 - -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011)
cSpanish and Portuguese synonymous terms were included.
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Search methods
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